The Roles of Biomarker Testing and HRCT in IPF and PPF

EP: 1.Symptoms, Manifestations and Mortality Rate of IPF

EP: 2.How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF

EP: 3.Epidemiology Facts, Differential Diagnosis, and Arriving at a IPF or PPF Diagnosis

EP: 4.Critical Early Diagnoses and Acute Exacerbations in IPF and PPF

EP: 5.Exploring the Role of Non-Pharmacological Modalities and Multidisciplinary Care in Patients with Idiopathic and Progressive Pulmonary Fibrosis

EP: 6.Managing Acute Exacerbations and the Psychosocial Aspect of Idiopathic and Progressive Pulmonary Fibrosis

EP: 7.Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis

Now Viewing

EP: 8.The Roles of Biomarker Testing and HRCT in IPF and PPF

EP: 9.Unmet Needs and the Role of AI in Earlier Disease Detection

EP: 10.Adverse Events Associated with Anti-Fibrotic Therapies

EP: 11.Investigational Agents for Idiopathic and Progressive Pulmonary Fibrosis

EP: 12.The Future of Idiopathic and Progressive Pulmonary Fibrosis Treatment

EP: 13.K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

Video content above is prompted by the following:

• What’s the role of biomarker testing in IPF and PPF and can it be used to differentiate IPF and PPF from other diseases?
• What’s the role of HRCT in identifying patients with IPF or PPF and what’s commonly seen on histopathology?